TMCnet - World's Largest Communications and Technology Community



49.0% Return Seen to Date on SmarTrend Cadence Pharmaceuticals Call (CADX)
[January 17, 2013]

49.0% Return Seen to Date on SmarTrend Cadence Pharmaceuticals Call (CADX)

Jan 17, 2013 (SmarTrend(R) Spotlight via COMTEX) -- SmarTrend identified an Uptrend for Cadence Pharmaceuticals (NASDAQ:CADX) on November 26th, 2012 at $3.65. In approximately 2 months, Cadence Pharmaceuticals has returned 48.97% as of today's recent price of $5.43.

In the past 52 weeks, shares of Cadence Pharmaceuticals have traded between a low of $2.56 and a high of $5.66 and are now at $5.43, which is 112% above that low price. In the last five trading sessions, the 50-day moving average (MA) has climbed 2.8% while the 200-day MA has risen 0.7%.

Cadence Pharmaceuticals, Inc. is a biopharmaceutical company that develops drugs for use in hospitals. The Company produces intravenous APAP for the treatment of acute pain and fever, and omiganan for the prevention of intravascular catheter-related infections.

SmarTrend will continue to scan these moving averages and a number of other proprietary indicators for any shifts in the trajectory of Cadence Pharmaceuticals shares.Log in and add Cadence Pharmaceuticals (CADX) to your watchlist today so you can receive a real-time alert when the shares are about to change trend.

Write to Chip Brian at --------------------------------------------------------------------------------------------- SmarTrend analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time. To get a free trial of our trading calls and maximize your trading results, please visit Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at:

[ Back To's Homepage ]

Technology Marketing Corporation

35 Nutmeg Drive Suite 340, Trumbull, Connecticut 06611 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments:
Comments about this site:


© 2017 Technology Marketing Corporation. All rights reserved | Privacy Policy